CNS Pharmaceuticals (CNSP) to Release Earnings on Monday

CNS Pharmaceuticals (NASDAQ:CNSP) is projected to release its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect the company to announce earnings of ($5.37) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

CNS Pharmaceuticals Price Performance

NASDAQ CNSP opened at $2.56 on Friday. The stock’s fifty day moving average price is $3.95 and its 200 day moving average price is $6.20. CNS Pharmaceuticals has a 1 year low of $2.06 and a 1 year high of $34.80. The company has a market cap of $1.59 million, a price-to-earnings ratio of -0.08 and a beta of 2.70.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Institutional Trading of CNS Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Boothbay Fund Management LLC purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter valued at $71,000. Ikarian Capital LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter worth $241,000. Finally, Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals during the second quarter worth $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.